CDKN2A and neoplasm: Various specific genetic alterations of individual members of the pRB-regulated pathway, including cyclin D, cdk4 and cyclin-dependent kinase inhibitor p16INK4a, contribute to the impairment of cell cycle control at the G1 S-phase transition in different tumour types.